BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, Kepp O. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology 2022;11:2077898. [DOI: 10.1080/2162402x.2022.2077898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, Govaerts J, Naulaerts S, Berneman ZN, Beuselinck B, Bol KF, Borst J, Coosemans A, Datsi A, Fučíková J, Kinget L, Neyns B, Schreibelt G, Smits E, Sorg RV, Spisek R, Thielemans K, Tuyaerts S, De Vleeschouwer S, de Vries IJM, Xiao Y, Garg AD. Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology 2022;11:2096363. [DOI: 10.1080/2162402x.2022.2096363] [Reference Citation Analysis]
2 Hong SH, Lee KS, Hwang HJ, Park SY, Han WK, Yoon YE. Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma. Genes (Basel) 2022;13:1211. [PMID: 35885994 DOI: 10.3390/genes13071211] [Reference Citation Analysis]
3 Kepp O, Bezu L, Kroemer G. The endoplasmic reticulum chaperone BiP: a target for immunogenic cell death inducers? Oncoimmunology 2022;11:2092328. [PMID: 35756845 DOI: 10.1080/2162402X.2022.2092328] [Reference Citation Analysis]